Were the Galectin Therapeutics (GALT) share sales under a Rule 10b5-1 plan?

Yes. The filing states the reported sale was made under a Rule 10b5-1 trading plan adopted on February 2, 2026. This plan was previously disclosed in Galectin Therapeutics’ Form 10-Q filed on May 15, 2026, indicating the trades were pre-arranged rather than discretionary.

Galectin Therapeutics (GALT) CMO sells 568 shares after option exercise

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Galectin Therapeutics Chief Medical Officer Jamil Khurram exercised options and sold shares in a routine, pre-planned transaction. On May 26, 2026, he exercised stock options to acquire 568 shares of common stock at an exercise price of $1.23 per share, then sold 568 shares in open-market trades at a weighted average price of $3.1004 per share.

The sale was made pursuant to a Rule 10b5-1 trading plan adopted on February 2, 2026 and previously disclosed in a Form 10-Q filed on May 15, 2026. Following these transactions, Khurram holds no common shares directly, while remaining stock options cover 40,057 shares at a $1.23 exercise price expiring on January 23, 2035.

Insider Trade Summary 10b5-1

Net Seller: 568 shares ($1,761)

Net Sell 3 txns

Insider Jamil Khurram

Role Chief Medical Officer

Sold 568 shs ($2K)

Type	Security	Shares	Price	Value
Exercise	Stock option (right to buy)	568	$0.00	--
Exercise	Common Stock	568	$1.23	$698.64
Sale	Common Stock	568	$3.1004	$2K

Holdings After Transaction: Stock option (right to buy) — 40,057 shares (Direct, null); Common Stock — 568 shares (Direct, null)

Footnotes (1)

The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026 The shares were sold in multiple transactions at prices ranging from $3.00 to $3.01. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. The options vest as follows: 16,250 on each of June 30, 2025, December 31, 2025, June 30, 2026, and December 31, 2026.

Key Figures

Shares sold: 568 shares Sale price (weighted average): $3.1004 per share Options exercised: 568 shares +4 more

7 metrics

Shares sold 568 shares Common stock sold on May 26, 2026

Sale price (weighted average) $3.1004 per share Open-market sale range $3.00–$3.01

Options exercised 568 shares Common stock acquired via option exercise

Option exercise price $1.23 per share Conversion or exercise price for options

Remaining options 40,057 options Stock options outstanding after transaction

Option expiration January 23, 2035 Expiration date of option grant

10b5-1 plan adoption date February 2, 2026 Plan governing the reported sale

Key Terms

Rule 10b5-1 plan, weighted average sale price, stock option (right to buy), open-market sale, +1 more

5 terms

Rule 10b5-1 plan financial

"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

weighted average sale price financial

"The shares were sold in multiple transactions at prices ranging from $3.00 to $3.01. This amount represents the weighted average sale price"

stock option (right to buy) financial

"Stock option (right to buy) with an exercise price of $1.23 per share expiring on January 23, 2035"

open-market sale financial

"transaction_action is described as an open-market sale of common stock"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

vesting financial

"The options vest as follows: 16,250 on each of June 30, 2025, December 31, 2025, June 30, 2026, and December 31, 2026."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Form 4 Insider Transactions: What Each Field Means →

05/28/2026 - 09:13 AM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jamil Khurram

(Last)

(First)

(Middle)

4960 PEACHTREE INDUSTRIAL BLVD

SUITE 240

(Street)

NORCROSS

GEORGIA

30071

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
GALECTIN THERAPEUTICS INC [ GALT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/26/2026		M⁽¹⁾		568	A	$1.23	568	D
Common Stock	05/26/2026		S⁽¹⁾		568	D	$3.1004⁽²⁾	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock option (right to buy)	$1.23	05/26/2026		M⁽¹⁾			568	12/31/2025⁽³⁾	01/23/2035	Common Stock	568	$0	40,057	D

Explanation of Responses:

1. The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026

2. The shares were sold in multiple transactions at prices ranging from $3.00 to $3.01. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

3. The options vest as follows: 16,250 on each of June 30, 2025, December 31, 2025, June 30, 2026, and December 31, 2026.

	Jack W. Callicutt, by power of attorney	05/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Galectin Therapeutics (GALT) CMO Jamil Khurram report in this Form 4?

Jamil Khurram reported exercising stock options for 568 Galectin Therapeutics shares at $1.23 each, then selling 568 common shares at a weighted average of $3.1004 per share. These transactions occurred on May 26, 2026 as disclosed in the Form 4 filing.

How many Galectin Therapeutics (GALT) shares did the CMO sell and at what price?

The Chief Medical Officer sold 568 shares of Galectin Therapeutics common stock in open-market transactions. The shares were sold at a weighted average price of $3.1004 per share, with individual trades executed between $3.00 and $3.01 according to the filing’s footnote.

What stock options did the Galectin Therapeutics (GALT) CMO exercise in this transaction?

He exercised stock options covering 568 shares of Galectin Therapeutics common stock at a conversion or exercise price of $1.23 per share. These options are part of a larger grant that vests in tranches during 2025 and 2026, as described in the footnotes.

Does the Galectin Therapeutics (GALT) CMO still hold shares after these transactions?

After the reported transactions, the Form 4 shows Jamil Khurram holding 0 common shares directly. However, he retains stock options representing 40,057 underlying shares with a $1.23 exercise price, expiring on January 23, 2035, indicating a remaining derivative position.

How many Galectin Therapeutics (GALT) stock options remain after this Form 4 transaction?

Following the exercise of 568 options, the Form 4 reports 40,057 stock options remaining. These options carry a $1.23 exercise price and expire on January 23, 2035. Vesting occurs in four installments on specified dates in 2025 and 2026.